PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-40

  1. 7,601 Posts.
    lightbulb Created with Sketch. 6870
    Same argument could have been competently made at $4 in 2020 for PAR running out of money before it gets there. PAR has always been a cash-burning business entity. Its progressed it regulatory pathways, albeit slowly, as this result very mildly does today.

    People letting their long-term stock price arguments sway discussion of these results. Standalone, good results, but on a very small trial. Regards MPS ambitions another small successful tick in the box in its pathways.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.5¢
Change
0.005(2.17%)
Mkt cap ! $82.20M
Open High Low Value Volume
23.5¢ 23.5¢ 23.0¢ $85.35K 365.1K

Buyers (Bids)

No. Vol. Price($)
10 280011 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 44703 3
View Market Depth
Last trade - 16.10pm 06/09/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.